Identification, characterization and predictive validation of a methylglyoxal signature in resectable pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine.

Summarise with VIRAT
Authors: Oier Azurmendi Senar
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

-Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal human malignancies, with a five-year survival rate below 12% and limited therapeutic progress over recent decades. Gemcitabine (GEM) continues to be a cornerstone of systemic treatment, yet only a subset of patients derives meaningful clinical benefit. Increasing evidence has highlighted the role of metabolic reprogramming and particularly enhanced glycolysis and the accumulation of the reactive metabolite methylglyoxal (MG) in promoting chemoresistance and tumor progression. Building on these insights, this study aimed to develop and validate a prognostic and predictive gene signature integrating MG-stress related biology with clinical outcomes in patients with resected PDAC treated with GEM. Three independent patient cohorts were analyzed (Puleo et al. n=309; Erasme University Hospital, n=60; and the PRODIGE24/CCTG PA6 phase III trial, n=350). Differential expression analysis between tumors with high and low MG stress identified 365 genes, from which a Least Absolute Shrinkage and Selection Operator (LASSO) Cox regression model was applied to derive a 16-gene signature termed MG-GEM. Using a weighted gene expression-based risk score, patients were classified into high- and low-risk groups, revealing strong stratification for both overall survival (OS) and disease-free survival (DFS). High MG-GEM tumors exhibited markedly shorter OS and DFS, independently of clinicopathological variables (HR=3.5, p

Fields of Study & Subjects

Pancreatic and Hepatic Oncology Research Breast Cancer Treatment Studies Cholangiocarcinoma and Gallbladder Cancer Studies

Publication details

Journal / source
Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles)
Publication date
3 March 2026
Language
EN
Document type
Thesis